MA55596A - Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement de cancers - Google Patents
Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement de cancersInfo
- Publication number
- MA55596A MA55596A MA055596A MA55596A MA55596A MA 55596 A MA55596 A MA 55596A MA 055596 A MA055596 A MA 055596A MA 55596 A MA55596 A MA 55596A MA 55596 A MA55596 A MA 55596A
- Authority
- MA
- Morocco
- Prior art keywords
- cancers
- treatment
- signaling pathway
- notch signaling
- pathway inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000005913 Notch signaling pathway Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19168508 | 2019-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55596A true MA55596A (fr) | 2022-02-16 |
Family
ID=66105107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055596A MA55596A (fr) | 2019-04-10 | 2020-04-09 | Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement de cancers |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220169642A1 (fr) |
| EP (1) | EP3953335A1 (fr) |
| JP (1) | JP7624930B2 (fr) |
| KR (1) | KR20220021462A (fr) |
| CN (2) | CN113966324B (fr) |
| AU (1) | AU2020271268B2 (fr) |
| BR (1) | BR112021020226A2 (fr) |
| CA (1) | CA3134791A1 (fr) |
| EA (1) | EA202192394A1 (fr) |
| IL (1) | IL287043B1 (fr) |
| MA (1) | MA55596A (fr) |
| MX (1) | MX2021012359A (fr) |
| PH (1) | PH12021552325A1 (fr) |
| SA (1) | SA521430519B1 (fr) |
| SG (1) | SG11202110545TA (fr) |
| TW (1) | TW202104166A (fr) |
| WO (1) | WO2020208139A1 (fr) |
| ZA (1) | ZA202108579B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4255409A1 (fr) | 2020-12-07 | 2023-10-11 | Cellestia Biotech AG | Combinaisons pharmaceutiques pour le traitement du cancer |
| EP4008324A1 (fr) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer |
| US20240269120A1 (en) | 2021-06-02 | 2024-08-15 | Cellestia Biotech Ag | Method for Treating an Autoimmune and Inflammatory Disease |
| WO2023079132A1 (fr) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Combinaisons pharmaceutiques pour le traitement du cancer |
| EP4223292A1 (fr) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Combinaisons pharmaceutiques pour le traitement du cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231931A (en) * | 1978-02-03 | 1980-11-04 | Ciba-Geigy Corporation | Tetraphenylketazines and isoindolinone pigments obtained therefrom |
| US4219474A (en) * | 1978-03-20 | 1980-08-26 | William H. Rorer, Inc. | Heterocyclic phenyl azo hydroxybenzenes |
| GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| JPH0748251A (ja) * | 1993-08-04 | 1995-02-21 | Green Cross Corp:The | 好酸球関連疾患予防治療剤 |
| US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
| DE69625709D1 (de) | 1995-09-29 | 2003-02-13 | Shionogi & Co | Alpha-substituierte heterozyklische benzylderivate, zwischenverbindungen zu ihrer herstellung und pestizide die diese als aktiver bestandteil enthalten |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| ES2202827T3 (es) * | 1997-03-19 | 2004-04-01 | ABBOTT GMBH & CO. KG | Pirrolo(2,3-d)pirimidinas y su uso como inhibidores de la tirosina kinasa. |
| JPH11152277A (ja) * | 1997-08-29 | 1999-06-08 | Takeda Chem Ind Ltd | トリアジン誘導体、その製造法及び用途 |
| US6365179B1 (en) | 1999-04-23 | 2002-04-02 | Alza Corporation | Conjugate having a cleavable linkage for use in a liposome |
| AUPR755501A0 (en) | 2001-09-07 | 2001-09-27 | Fujisawa Pharmaceutical Co., Ltd. | Cyclic compound |
| BR0206161A (pt) * | 2001-10-19 | 2005-02-01 | Ortho Mcneil Pharm Inc | 2-fenil benzimidazóis e imidazo-[4,5]-piridinas como inibidores de cds1/chk2 e adjuvantes para quimioterapia ou terapia por radiação no tratamento de câncer |
| US20050214250A1 (en) | 2003-11-06 | 2005-09-29 | Harris J M | Method of preparing carboxylic acid functionalized polymers |
| EP1781595A1 (fr) * | 2004-08-13 | 2007-05-09 | Praecis Pharmaceuticals Inc. | Procedes et compositions servant a moduler l'activite du recepteur de la sphingosine-1-phosphate (s1p) |
| EP1969934A1 (fr) * | 2007-03-12 | 2008-09-17 | Bayer CropScience AG | Phénoxyphénylamidine substituée par 4 cycloalkyl ou 4 aryl et son utilisation en tant que fongicide |
| AR068072A1 (es) * | 2007-04-19 | 2009-11-04 | Novartis Ag | Derivados de bencimidazoles, composiciones farmaceuticas y usos |
| GB0722055D0 (en) * | 2007-11-09 | 2007-12-19 | Argenta Discovery Ltd | Compounds |
| JPWO2013035827A1 (ja) | 2011-09-09 | 2015-03-23 | 塩野義製薬株式会社 | 新規オレフィン誘導体 |
| EP2606884A1 (fr) * | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement des cancers |
| CN103788371B (zh) * | 2014-01-28 | 2016-08-24 | 中国科学院兰州化学物理研究所 | 含噻唑环二胺化合物在制备太阳能吸热涂料中的应用 |
| CN109134336B (zh) * | 2017-10-27 | 2021-08-03 | 北京大学深圳研究生院 | 二芳醚类化合物及其制备方法和应用 |
| KR102866499B1 (ko) * | 2019-03-15 | 2025-10-02 | 더 제너럴 하스피탈 코포레이션 | Tead 전사인자의 신규한 소분자 저해제 |
-
2020
- 2020-04-09 PH PH1/2021/552325A patent/PH12021552325A1/en unknown
- 2020-04-09 MA MA055596A patent/MA55596A/fr unknown
- 2020-04-09 CN CN202080043231.4A patent/CN113966324B/zh active Active
- 2020-04-09 EA EA202192394A patent/EA202192394A1/ru unknown
- 2020-04-09 JP JP2021559902A patent/JP7624930B2/ja active Active
- 2020-04-09 WO PCT/EP2020/060153 patent/WO2020208139A1/fr not_active Ceased
- 2020-04-09 KR KR1020217036445A patent/KR20220021462A/ko active Pending
- 2020-04-09 MX MX2021012359A patent/MX2021012359A/es unknown
- 2020-04-09 CN CN202411128418.0A patent/CN118994001A/zh active Pending
- 2020-04-09 AU AU2020271268A patent/AU2020271268B2/en active Active
- 2020-04-09 IL IL287043A patent/IL287043B1/en unknown
- 2020-04-09 CA CA3134791A patent/CA3134791A1/fr active Pending
- 2020-04-09 BR BR112021020226A patent/BR112021020226A2/pt unknown
- 2020-04-09 SG SG11202110545TA patent/SG11202110545TA/en unknown
- 2020-04-09 US US17/602,959 patent/US20220169642A1/en active Pending
- 2020-04-09 TW TW109111945A patent/TW202104166A/zh unknown
- 2020-04-09 EP EP20717868.2A patent/EP3953335A1/fr active Pending
-
2021
- 2021-10-06 SA SA521430519A patent/SA521430519B1/ar unknown
- 2021-11-03 ZA ZA2021/08579A patent/ZA202108579B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202110545TA (en) | 2021-10-28 |
| MX2021012359A (es) | 2022-01-19 |
| AU2020271268A1 (en) | 2021-10-28 |
| PH12021552325A1 (en) | 2022-06-27 |
| JP7624930B2 (ja) | 2025-01-31 |
| CN118994001A (zh) | 2024-11-22 |
| IL287043B1 (en) | 2025-10-01 |
| ZA202108579B (en) | 2024-03-27 |
| WO2020208139A1 (fr) | 2020-10-15 |
| CN113966324A (zh) | 2022-01-21 |
| US20220169642A1 (en) | 2022-06-02 |
| CN113966324B (zh) | 2024-09-03 |
| EP3953335A1 (fr) | 2022-02-16 |
| CA3134791A1 (fr) | 2020-10-15 |
| JP2022529324A (ja) | 2022-06-21 |
| TW202104166A (zh) | 2021-02-01 |
| EA202192394A1 (ru) | 2022-01-24 |
| BR112021020226A2 (pt) | 2021-12-07 |
| SA521430519B1 (ar) | 2025-06-15 |
| KR20220021462A (ko) | 2022-02-22 |
| AU2020271268B2 (en) | 2025-11-20 |
| IL287043A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55596A (fr) | Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement de cancers | |
| EP3332783C0 (fr) | Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement des cancers | |
| MA45122A (fr) | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer | |
| MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
| MA50790A (fr) | Posologie de vidofludimus à utiliser dans la prévention ou le traitement de maladies inflammatoires chroniques et/ou auto-immunes | |
| MA52886A (fr) | Composés de purinone et leur utilisation dans le traitement du cancer | |
| EP3937980A4 (fr) | Miarn modifiés et leur utilisation dans le traitement du cancer | |
| EP3796920A4 (fr) | Compositions d'arnt/pré-miarn et leur utilisation dans le traitement du cancer | |
| EP3463315A4 (fr) | Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale | |
| EP3609515A4 (fr) | Procédés pour le traitement d'une inflammation et d'affections inflammatoires | |
| MA45089A (fr) | Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes | |
| EP3635130A4 (fr) | Médicament de précision pour le traitement et la prévention du risque suicidaire | |
| MA56392A (fr) | Dérivés de 2h-indazole et leur utilisation dans le traitement de maladies | |
| MA47450A (fr) | Sulfinylpyridines et leur utilisation dans le traitement du cancer | |
| MA43767A (fr) | Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer | |
| MA47069A (fr) | Formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires | |
| EP3331526A4 (fr) | Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine | |
| MA47452A (fr) | Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer | |
| EP3735970C0 (fr) | Cébranopadol pour le traitement de la douleur chez des sujets à fonction hépatique altérée et/ou fonction rénale altérée | |
| MA46085A (fr) | Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires | |
| EP3307069A4 (fr) | Utilisation du telmisartan pour la prévention et le traitement de la maladie du greffon contre l'hôte et d'autres maladies auto-immunes et allo-immunes | |
| MA47451A (fr) | Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA47458A (fr) | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer | |
| EP3541409A4 (fr) | Monomères de tgf-bêta modifiés et leur utilisation pour inhiber la signalisation de tgf-bêta | |
| EP3749342A4 (fr) | Bactériophage pour le traitement et la prévention de cancers associés à des bactéries |